falsefalse

Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice - Episode 2

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

, , ,

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
    Now Viewing
    EP. 2: The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC
    EP. 3: Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials
    EP. 4: Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC
    EP. 5: Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial
    EP. 6: The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC
    EP. 7: Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC
    EP. 8: Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors
    EP. 9: CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
    EP. 10: KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC
    EP. 11: EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC
    EP. 12: POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC
    EP. 13: Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
    EP. 14: The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC
    EP. 15: The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC
    EP. 16: A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations
    EP. 17: The Exciting Future of NSCLC Treatment
    EP. 18: Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
    EP. 19: POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations
    EP. 20: Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
    EP. 21: Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations
    EP. 22: Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

    Related Content:

    Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical PracticeOncLive Peer Exchange® Lung CancerImmunotherapy in Lung Cancer
    First-Line Ivonescimab Plus Chemo Improves PFS in Advanced Squamous NSCLC
    Updated ASCO Living Guidelines Highlight Need for Timely, Patient-Friendly Communication in Stage IV NSCLC
    Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement
    x